From what 8 stock analysts predict, the share price for STERIS PLC (STE) might increase by 10.62% in the next year. This is based on a 12-month average estimation for STE. Price targets go from $230 to $265. The majority of stock analysts believe STE is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
STERIS PLC has a total of 8 Wall St Analyst ratings. There are 6 buy ratings, 2 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that STERIS PLC will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of STE.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Jason Bednar Piper Sandler | Overweight | $260 | Upgrade | Oct 24, 2024 |
Brett Fishbin Keybanc | Overweight | $265 | Maintains | Sep 3, 2024 |
Mike Matson Needham | Hold | Reiterates | Aug 8, 2024 | |
David Turkaly JMP Securities | Market Outperform | $265 | Reiterates | Aug 7, 2024 |
Jacob Johnson Stephens & Co. | Overweight | $260 | Reiterates | Aug 7, 2024 |
David Turkaly JMP Securities | Market Outperform | $265 | Reiterates | Jul 26, 2024 |
Jason Bednar Piper Sandler | Neutral | $225 | Reiterates | May 10, 2024 |
Mike Matson Needham | Hold | Reiterates | May 10, 2024 | |
David Turkaly JMP Securities | Market Outperform | $265 | Reiterates | May 9, 2024 |
Mike Matson Needham | Hold | Reiterates | Apr 12, 2024 | |
Jacob Johnson Stephens & Co. | Overweight | $250 | Reiterates | Feb 9, 2024 |
David Turkaly JMP Securities | Market Outperform | $265 | Reiterates | Feb 8, 2024 |
Brett Fishbin Keybanc | Overweight | $253 | Initiates | Feb 6, 2024 |
Patrick Wood Morgan Stanley | Equal-Weight | $215 | Maintains | Dec 4, 2023 |
David Turkaly JMP Securities | Market Outperform | $265 | Reiterates | Nov 9, 2023 |
Jason Bednar Piper Sandler | Neutral | $215 | Maintains | Oct 27, 2023 |
Jason Bednar Piper Sandler | Neutral | $215 | Maintains | Oct 26, 2023 |
Jacob Johnson Stephens & Co. | Overweight | $250 | Reiterates | Sep 25, 2023 |
David Turkaly JMP Securities | Market Outperform | $265 | Maintains | Sep 1, 2023 |
Patrick Wood Morgan Stanley | Equal-Weight | $225 | Maintains | Aug 3, 2023 |
When did it IPO
1992
Staff Count
18,000
Country
United States
Sector/Industry
Healthcare/Medical Devices
CEO
Mr. Daniel A. Carestio
Market Cap
$22.27B
In 2023, STE generated $4.54B in revenue, which was a increase of 7.41% from the previous year. This can be seen as a signal that STE's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - STERIS plc (NYSE: STE) will pay a quarterly dividend of $0.57 per share on December 19, 2024, to shareholders recorded by November 19, 2024.
Why It Matters - STERIS plc's announcement of a quarterly dividend indicates financial stability and commitment to returning value to shareholders, which can attract investors seeking income-generating stocks.
Summary - Steris (STE) is expected to report strong earnings due to favorable conditions. Investors should prepare for key expectations ahead of the earnings report.
Why It Matters - Steris's potential earnings beat may signal strong financial performance, boosting investor confidence and possibly increasing share price ahead of the report.
Summary - Analysts are evaluating Steris's performance for Q3 2024, focusing on key metrics beyond top and bottom-line estimates to gain insights into the company's business performance.
Why It Matters - Evaluating key metrics beyond estimates provides insights into Steris's operational performance and future growth potential, influencing investment decisions and stock valuations.
Summary - STERIS plc (NYSE: STE) will host a conference call on November 7, 2024, at 9:00 a.m. ET to discuss its fiscal 2025 Q2 financial results. Details available at www.steris-ir.com.
Why It Matters - STERIS plc's upcoming conference call on fiscal Q2 results may impact stock performance and investor sentiment, providing insights into financial health and future guidance.
Summary - STERIS is expected to report positive second-quarter fiscal 2025 results due to the normalization of its Healthcare backlog.
Why It Matters - STERIS' improved second-quarter results indicate a recovering healthcare backlog, suggesting potential revenue growth and operational efficiency, positively impacting investor sentiment.
Summary - STERIS plc has secured a $1.1 billion revolving credit facility, replacing its prior agreement, effective October 7, 2024, facilitated by JPMorgan Chase Bank.
Why It Matters - STERIS plc's $1.1 billion revolving credit facility enhances liquidity, providing financial flexibility for growth or debt management, which can positively impact stock performance and investor confidence.